BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther 2019;19:1031-43. [PMID: 30574813 DOI: 10.1080/14712598.2019.1561851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG. Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review. J Clin Med 2022;11. [PMID: 36498816 DOI: 10.3390/jcm11237240] [Reference Citation Analysis]
2 Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. Sci Rep 2022;12:19569. [PMID: 36380105 DOI: 10.1038/s41598-022-24050-7] [Reference Citation Analysis]
3 Burlando M, Fabbrocini G, Marasca C, Dapavo P, Chiricozzi A, Malvaso D, Dini V, Campanati A, Offidani A, Dattola A, Caro RDC, Bianchi L, Venturini M, Gisondi P, Guarneri C, Malara G, Trifirò C, Malagoli P, Fargnoli MC, Piaserico S, Carmisciano L, Castelli R, Parodi A. Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study. Biomedicines 2022;10:2522. [PMID: 36289787 DOI: 10.3390/biomedicines10102522] [Reference Citation Analysis]
4 Cantini F, Goletti D, Benucci M, Foti R, Damiani A, Niccoli L. Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. Expert Opin Drug Saf 2021;:1-11. [PMID: 34937466 DOI: 10.1080/14740338.2022.2020247] [Reference Citation Analysis]
5 Mrowietz U. Biosimilars für Psoriasis und Psoriasis-Arthritis. hautnah dermatologie 2020;36:24-25. [DOI: 10.1007/s15012-019-0005-8] [Reference Citation Analysis]